Phase 4
Completed N=13
The Effect of Brimonidine
Intraocular Pressure
Source: ClinicalTrials.gov NCT03959176 ↗
Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcomePrimary: Intraocular Pressure — 15.4; 16.3; 16.5; 16.7 millimeters of mercury (mmHg)
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will evaluate whether pre-treating patients with Brimonidine 0.2% before and/or after dilating the pupils will help to control the changes in intraocular pressure often seen when using dilating drops. The study will also evaluate the effects of different sequences of administering dilating drops along with Brimonidine on pupil size and reactivity.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraocular Pressure |
12.4; 9.3; 11.0; 13.7 | — |
| SECONDARY Pupil Size |
7.6; 7.6; 6.7; 7.6 | — |
| SECONDARY Pupil Reaction to Light |
1; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy individuals
- Females of childbearing potential must agree to use a reliable method of birth control while participating in the study.
Exclusion Criteria
- Diabetic
- Have a history of glaucoma
- Have a history of iris trauma
- Have a history of eye surgery except for LASIK or PRK
- Pregnant
- Anisocoria (unequal pupils)
Data sourced from ClinicalTrials.gov (NCT03959176). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.